Get the Stockscreener App
0.796
34.92%
0.206
Aprea Therapeutics Inc stock is traded at $0.796, with a volume of 109.31M.
It is up +34.92% in the last 24 hours and down -10.56% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$0.59
Open:
$0.6149
24h Volume:
109.31M
Relative Volume:
60.31
Market Cap:
$5.57M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.1995
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-4.10%
1M Performance:
-10.56%
6M Performance:
-56.74%
1Y Performance:
-79.05%
1-Day Range:
$0.61
$1.49
1-Week Range:
$0.548
$1.49
52-Week Range:
$0.548
$4.65
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.796 | 4.13M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aprea Therapeutics raises $5.6 million in private placement By Investing.com - Investing.com Nigeria
Aprea reports first partial response in Phase 1 cancer drug trial By Investing.com - Investing.com South Africa
Aprea Therapeutics Signs Multiple Material Agreements - TradingView
Aprea Therapeutics (APRE) Price Target Lowered to $4.00 by HC Wa - GuruFocus
What is Aprea Therapeutics Inc.’s market position2025 Valuation Update & Long Hold Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Aprea reports first partial response in Phase 1 cancer drug trial - Investing.com India
Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint - StockInvest.us
Aprea Therapeutics stock falls after early-stage cancer drug data By Investing.com - Investing.com Nigeria
Aprea Therapeutics stock falls after early-stage cancer drug data - Investing.com
Aprea Therapeutics prices $5.6M private placement - MSN
Aprea Therapeutics raises $5.6 million in private placement - Investing.com
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics Reports Early Clinical Activity of APR-1051 in Advanced Endometrial Cancer with Significant Tumor Reduction - Quiver Quantitative
Experimental cancer drug APR-1051 shrinks tumor 50% in early Aprea trial - Stock Titan
Aprea Therapeutics, Inc. announced that it expects to receive $5.597083 million in funding - marketscreener.com
How cyclical is Aprea Therapeutics Inc.’s revenue streamJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - mfd.ru
AI Stocks: Is MCHPs ROE strong enough2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Aprea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Fed Meeting: How cyclical is Purple Biotech Ltd Depositary Receipts revenue streamMarket Movers & Reliable Breakout Forecasts - baoquankhu1.vn
Profit Review: Is DGXX undervalued by DCF analysis2025 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
New Strong Sell Stocks for January 19th - Zacks Investment Research
Is Aprea Therapeutics Inc stock a buy or sellJuly 2025 Volume & High Accuracy Investment Entry Signals - baoquankhu1.vn
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN
Levels Update: Is Aprea Therapeutics Inc affected by consumer sentimentEarnings Overview Report & Growth Focused Stock Reports - baoquankhu1.vn
Aprea Therapeutics (NASDAQ:APRE) Cut to “Strong Sell” at Zacks Research - Defense World
Short Covering: Is Aprea Therapeutics Inc backed by strong institutional buyingQuarterly Investment Review & Safe Capital Growth Stock Tips - baoquankhu1.vn
New Strong Sell Stocks for Jan. 14 - sharewise.com
Is Aprea Therapeutics Inc affected by consumer sentimentJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
MSN Money - MSN
Aprea Therapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets
Why Aprea Therapeutics Inc. stock is a value investor pickEarnings Risk Report & Weekly Hot Stock Watchlists - Улправда
Why retail investors favor Aprea Therapeutics Inc. stockMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Why Aprea Therapeutics Inc. stock is considered a top pickJuly 2025 Analyst Calls & Weekly High Conviction Ideas - Улправда
Will Aprea Therapeutics Inc. stock outperform growth indexesInsider Selling & Weekly Setup with High ROI Potential - Улправда
Can Aprea Therapeutics Inc. stock reach $100 price targetM&A Rumor & High Accuracy Trade Signal Alerts - Улправда
Will Aprea Therapeutics Inc. stock reach all time highs in 2025Sell Signal & Technical Confirmation Alerts - Улправда
Dow Theory LettersAprea Therapeutics, Inc.Common Stock (Nasdaq:APRE) Price Chart - FinancialContent
Will Aprea Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Why retail investors pile into Aprea Therapeutics Inc. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - Улправда
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Aprea Therapeutics files to sell 5.5M shares of common stock for holders - MSN
Aprea signals 2026 inflection as cancer trials advance and cash extends - MSN
Market Recap: Will Aprea Therapeutics Inc stock reach all time highs in 2025 - moha.gov.vn
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December - Defense World
Aprea Therapeutics (NASDAQ:APRE) vs. Affymax (OTCMKTS:AFFY) Financial Survey - Defense World
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Quantisnow
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):